Clinical trial of voriconazole in Europe and the United States

Research output: Contribution to journalArticlepeer-review


Aspergillus has recently replaced Candida as the primary cause of death due to fungal infection, making it urgent to find drugs with good activity against Aspergillus. The new azole antifungal voriconazole (VRCZ) showed greater effectiveness and tolerability against aspergillosis than the conventional gold standard, Amphotericin B (AMPH). It also improved the survival of invasive aspergillosis patients with unfavorable prognosis. Earlier treatment with VRCZ would be expected to result in even better effectiveness and survival. Empiric treatment with VRCZ is expected to effectively prevent the onset of aspergillosis in high-risk patients.

Original languageEnglish (US)
Pages (from-to)24-31
Number of pages8
JournalJapanese Journal of Chemotherapy
Issue numberSUPPL. 2
StatePublished - Nov 1 2005


  • Aspergillosis
  • Combination therapy
  • Early treatment
  • Invasive pulmonary aspergillosis
  • Voriconazole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Clinical trial of voriconazole in Europe and the United States'. Together they form a unique fingerprint.

Cite this